Applying Experience from the Management of Infectious Diseases to Address the Rise of Chronic Illness in the Developing World

_Sponsored by: Navartis Social Buisness_

Monday, November 14, 2016 7:15 p.m. – 9 p.m.

Novartis has a wealth of experience in tackling infectious diseases through the Malaria Initiative business and is also leading in operational innovation in social business models to target non-communicable diseases (NCDs) with the launch of the Novartis Access business for NCD medicines in low-income countries. This session is intended to cover themes of Access to Medicines by applying learnings from Malaria to the rising tide of NCDs. The panelists will discuss how the progress in the fight against Malaria contributes to higher life expectancy and the rise of NCDs, the policy and operational implications of addressing the dual burden of diseases, how learning from impact measurement from infectious diseases can inform M&E for future Access initiatives for chronic diseases, and what is the vision to lead the pharmaceutical industry in Sustainable Development Goals era.

CHAIR
Richard G. Marlink
_Director, Rutgers Global Health Institute, Founding Henry Rutgers Professor of Global Health, Rutgers Biomedical Health Sciences (RBHS), New Brunswick, NJ, United States_

PROGRESS IN MALARIA CONTROL AND ELIMINATION AND THE RISE OF NON-COMMUNICABLE DISEASES
Charles Nelson
_Chief Executive, Malaria Consortium, London, United Kingdom_

EVALUATING THE IMPACT OF ACCESS TO MEDICINES PROGRAMS
Peter Rockers
_Assistant Professor, Global Health, Boston University School of Public Health, Boston, MA, United States_

MINISTRY OF HEALTH PERSPECTIVE ON POLICY AND OPERATIONAL IMPLICATIONS WHEN ADDRESSING DUAL DISEASE BURDEN
Marie Aimee Muhimpundu
_Medical Epidemiologist, NCD Unit, Rwanda Biomedical Centre, Kigali, Rwanda_

THE NOVARTIS VISION TO LEAD THE PHARMACEUTICAL INDUSTRY IN THE SUSTAINABLE DEVELOPMENT GOALS ERA
Harald Nusser
_Global Head, Novartis Malaria Initiative and Novartis Access, Basel, Switzerland_